Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.
Canadian Study Highlights Care Variability for Older Patients With MDS/AML
December 19th 2024A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
Luspatercept Promising Against Anemia in MDS
December 18th 2024Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
New Study Evaluates Quality-of-Life Instruments for Patients With PAH
December 12th 2024A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.
Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis
December 1st 2024Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita
November 8th 2024A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing allogeneic hematopoietic cell transplantation did not negatively affect survival or increase complications.
Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine
November 8th 2024Researchers introduce a telemedicine system powered by artificial intelligence (AI) that automatically scores neuromuscular examinations, offering the potential to enhance patient monitoring, reduce variability in clinical trials, and improve access to care for neuromuscular disorders like myasthenia gravis.
CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications
October 17th 2024A new study reviews how various routes of adeno-associated virus (AAV) gene therapy administration influence local and peripheral immune responses, with a focus on those observed in clinical trials targeting the central nervous system (CNS).
New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+
October 3rd 2024Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant
September 20th 2024A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL
September 12th 2024The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.